Licensed Practical Nurse in Fort Sill, OK Accepting Medicare

6 Licensed Practical Nurse nurses found. Showing 1 - 6

Craig Reavis, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-2772

Ms. Teresa A Benjamin, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4303 Pitman Road, Fort Sill, OK 73503 Phone: 580-351-1131

Andrew Wilkins, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-678-7699

Mrs. Darlene Ann Streeter, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-8294    Fax: 580-558-2470

Lilla Brown, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-2000    Fax: 580-558-2885

Tonya Estep, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-8237

News Archive

Drug brand name can influence treatment decisions by patients

The brand name of a drug can strongly influence treatment decisions by patients, according to a randomized trial of decision aids by researchers from McMaster University.

NIH award reflects urgency of overcoming infections that resist drug treatment

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients.

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

Read more Medical News

› Verified 7 days ago